Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

2(50.0%)

Phase 2

1(25.0%)

Phase 3

1(25.0%)

4Total

Phase 1(2)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT01944774Phase 2Completed

Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Malate Sodium Chloride

Role: collaborator

NCT02238834Phase 1Completed

Phase 1 Safety, Tolerability and Pharmacokinetics (PK) Study of FP-025 in Healthy Volunteers

Role: collaborator

NCT02712320Phase 3Completed

Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg

Role: collaborator

NCT02803762Phase 1Completed

Investigate Absorption, Metabolism, Excretion, and Mass Balance of Pacritinib

Role: collaborator

All 4 trials loaded